Several other brokerages have also recently issued reports on KRYS. BidaskClub upgraded Krystal Biotech from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, November 27th. Guggenheim set a $81.00 price objective on Krystal Biotech and gave the stock a “buy” rating in a research note on Thursday, September 26th. William Blair restated a “buy” rating on shares of Krystal Biotech in a research note on Monday, November 4th. Goldman Sachs Group began coverage on Krystal Biotech in a research note on Tuesday, September 24th. They set a “neutral” rating and a $60.00 price objective on the stock. Finally, Cowen restated a “buy” rating on shares of Krystal Biotech in a research note on Tuesday, November 5th. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $59.33.
Shares of KRYS opened at $61.54 on Tuesday. The business’s fifty day moving average price is $45.77 and its 200 day moving average price is $41.58. Krystal Biotech has a 12-month low of $16.82 and a 12-month high of $63.51. The stock has a market capitalization of $992.56 million, a PE ratio of -63.44 and a beta of 1.19. The company has a debt-to-equity ratio of 0.01, a current ratio of 54.87 and a quick ratio of 54.87.
In other Krystal Biotech news, CEO Krish S. Krishnan sold 22,121 shares of the firm’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $52.33, for a total value of $1,157,591.93. Following the sale, the chief executive officer now directly owns 2,024,567 shares in the company, valued at $105,945,591.11. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Krish S. Krishnan sold 27,879 shares of the firm’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $50.41, for a total value of $1,405,380.39. Following the completion of the sale, the chief executive officer now owns 2,024,567 shares in the company, valued at $102,058,422.47. The disclosure for this sale can be found here. Company insiders own 34.30% of the company’s stock.
Hedge funds have recently bought and sold shares of the business. Bank of Montreal Can bought a new stake in Krystal Biotech in the second quarter valued at $29,000. Tower Research Capital LLC TRC bought a new stake in Krystal Biotech in the second quarter valued at $72,000. Strs Ohio bought a new stake in Krystal Biotech in the second quarter valued at $92,000. Metropolitan Life Insurance Co NY bought a new stake in Krystal Biotech in the third quarter valued at $113,000. Finally, Rhumbline Advisers lifted its stake in Krystal Biotech by 18.6% in the third quarter. Rhumbline Advisers now owns 10,270 shares of the company’s stock valued at $357,000 after buying an additional 1,614 shares during the last quarter. Institutional investors own 64.64% of the company’s stock.
About Krystal Biotech
Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in Phase II of a Phase I/II clinical study to treat dystrophic epidermolysis bullosa, a genetic disease.
Read More: Buyback
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.